Recombinant Human CCNB1, N-His

Description of Recombinant Human CCNB1, N-His

Introduction

Recombinant human CCNB1, also known as cyclin B1, is a protein that plays a crucial role in cell cycle regulation. It is a member of the cyclin family of proteins and is involved in the transition from G2 phase to mitosis. CCNB1 has been identified as a potential drug target due to its essential role in cell division and its involvement in various diseases. In this article, we will discuss the structure, activity, and application of recombinant human CCNB1.

Structure of Recombinant Human CCNB1

The gene encoding for human CCNB1 is located on chromosome 5 and consists of 7 exons. The protein is composed of 433 amino acids and has a molecular weight of approximately 48 kDa. CCNB1 contains two main domains, the N-terminal domain and the C-terminal domain. The N-terminal domain is responsible for binding to cyclin-dependent kinase 1 (CDK1), while the C-terminal domain is involved in the regulation of protein stability and nuclear localization.

CCNB1 also contains a destruction box (D-box) motif that is essential for its degradation during the cell cycle. This motif is recognized by the anaphase-promoting complex/cyclosome (APC/C), which marks CCNB1 for degradation by the proteasome, allowing for the progression of the cell cycle.

Activity of Recombinant Human CCNB1

CCNB1 is a key regulator of the G2/M transition in the cell cycle. It forms a complex with CDK1, which is activated by phosphorylation, leading to the activation of CCNB1. This complex then promotes the transition from G2 phase to mitosis by phosphorylating downstream targets involved in mitotic entry and progression.

In addition to its role in cell cycle regulation, CCNB1 has also been found to have other functions. It has been shown to play a role in DNA repair by promoting the recruitment of DNA repair proteins to sites of DNA damage. CCNB1 has also been implicated in regulating cellular metabolism and apoptosis.

Application of Recombinant Human CCNB1

Due to its essential role in cell cycle regulation, CCNB1 has been identified as a potential drug target for various diseases. One of the most promising applications of recombinant human CCNB1 is in cancer treatment. Many cancer cells have been found to overexpress CCNB1, leading to uncontrolled cell growth and proliferation. Targeting CCNB1 with specific inhibitors has shown promising results in inhibiting cancer cell growth and inducing cell death.

CCNB1 has also been studied as a potential target for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. These diseases are characterized by abnormal cell cycle activity, and targeting CCNB1 could potentially help regulate cell cycle progression and prevent neuronal death.

In addition to its potential as a drug target, recombinant human CCNB1 has also been used in research and diagnostic applications. It is commonly used as a marker for cell cycle progression in cell culture experiments and can also be detected in tissue samples to assess the proliferation rate of cancer cells.

Conclusion

In summary, recombinant human CCNB1 is a crucial protein involved in cell cycle regulation. Its structure, activity, and potential applications make it a promising drug target for various diseases, particularly cancer. Further research on CCNB1 and its interactions with other proteins may provide new insights into its role in disease and potential therapeutic interventions.